RADIUM-224 ADSORBED IN CALCIUM CARBONATE MICROPARTICLES for High-grade serous ovarian cancer|High-grade endometrioid ovarian cancer|Primary peritoneal cancer|Peritoneal carcinomatosis

Inclusion criteria

• {"criterion_text":"- Able and willing to provide written informed consent and to comply with the clinical study protocol (CSP)."}
• {"criterion_text":"- HR-proficient tumour based on available testing, or HR result inconclusive, provided there are no known somatic or germline BRCA1/2 mutations."}
• {"criterion_text":"- Received NACT (numbers of cycles as per investigator’s discretion) with regress or stable disease on diagnostic imaging and assessed to be operable to R0 pre-surgery."}
• {"criterion_text":"- Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 to 2 and patient fit enough to undergo IDS and further treatment according to standard of care."}
• {"criterion_text":"- Adequate renal function: Calculated creatinine clearance using the Cockcroft-Gault formula ≥ 40 ml/min or measured creatinine clearance ≥ 40 ml/min."}
• {"criterion_text":"- Adequate hepatic function: 1) Serum bilirubin < 1.5 x upper limit of normal (ULN), and 2) Aspartate transaminase and alanine transaminase ≤ 3 x ULN."}
• {"criterion_text":"- Adequate bone marrow function: 1) Absolute neutrophil count ≥ 1.0 x 10^9/l, and 2) Platelets ≥ 100 x 10^9/l, and 3) Haemoglobin ≥ 9 g/dL."}
• {"criterion_text":"- For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment."}
• {"criterion_text":"- For females of childbearing potential agreement to use at least one of the following highly effective (failure rate < 1%) methods of contraception during the treatment period and for at least 9 months if they receive Radspherin®, unless hysterectomy or oophorectomy is performed during IDS. 1) Total abstinence (when this is in line with the preferred and usual lifestyle of the patient), periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 2) Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before enrolment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment. 3) Use of oral (oestrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Note: In addition to the use of one highly effective method of contraception as listed above, a condom is required for all male partners during the treatment period and for at least 9 months after the dose of IMP, unless vasectomised at least 6 months prior to enrolment."}
• {"criterion_text":"- Female of age ≥ 18 years."}
• {"criterion_text":"- Patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO Stage IIIB/C or IV)."}
• {"criterion_text":"- Peritoneal and other metastases eligible for IDS to no residual tumour."}
• {"criterion_text":"- Adverse events recovered to at least Grade 1 from the effects (excluding alopecia) of any prior medical therapy for malignancy."}

Exclusion criteria

• {"criterion_text":"- Confirmed HR deficient."}
• {"criterion_text":"- Active liver disease with positive serology for active hepatitis B, hepatitis C or known human immunodeficiency virus (HIV)."}
• {"criterion_text":"- Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease."}
• {"criterion_text":"- Any condition or illness that, in the opinion of the investigator or the medical monitor, would compromise the safety of the patients or interfere with the evaluation of the safety of the investigational medicinal product."}
• {"criterion_text":"- In the investigator’s opinion not able to comply with study procedures. Any medical or psychological condition that would preclude participation in the study or compromise the ability to give informed consent."}
• {"criterion_text":"- Administration of an investigational medicinal product within 4 weeks, or at least 5 times the half-life, prior to enrolment."}
• {"criterion_text":"- Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to, and up to 4 weeks after the surgery."}
• {"criterion_text":"- Treatment with bevacizumab within 5 weeks prior to IDS."}
• {"criterion_text":"- Known hypersensitivity to any of the excipients of the study drug."}
• {"criterion_text":"- Suspicion of peritoneal leak, shunt, or otherwise suspected atypical target compartment pharmacokinetics, based on investigator’s judgement, patient history and diagnostic images."}
• {"criterion_text":"- Epithelial borderline tumours, ovarian clear cell carcinoma, mucinous ovarian carcinoma, malignant Brenner tumours, non-epithelial ovarian malignancies, carcinosarcoma and neuroendocrine tumours or recurrent ovarian cancer."}
• {"criterion_text":"- Symptomatic central nervous system metastasis."}
• {"criterion_text":"- Another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cutaneous melanoma stage 1, cervical cancer in situ or FIGO 2023 Stage IA1 or IA3 prior or synchronous endometrial cancer)."}
• {"criterion_text":"- Prior abdominal/pelvic radiotherapy."}
• {"criterion_text":"- Disease progression during NACT."}
• {"criterion_text":"- Pregnant or lactating (nursing) women."}
• {"criterion_text":"- Active infections requiring antibiotics, and/or physician monitoring, or recurrent fever > 38.0 ⁰C associated with a clinical diagnosis of active infection."}

Primary endpoints

• {"endpoint_text":"- PFS defined as time from randomisation until the date of first progression or death, whichever occurs first. PFS will be assessed using computed tomography (CT) or magnetic resonance imaging (MRI) and according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.","definition_or_measurement_approach":"Time from randomisation until first progression or death; assessed using CT or MRI and according to RECIST v1.1."}

Secondary endpoints

• {"endpoint_text":"- OS defined as time from date of randomisation until the date of death from any cause.","definition_or_measurement_approach":"Time from randomisation until death from any cause."}
• {"endpoint_text":"- PPFS defined as the date from randomisation until the date of first progression in the peritoneum or death for any cause, whichever occurs first. PPFS will be assessed using CT/MRI and according to RECIST v1.1.","definition_or_measurement_approach":"Time from randomisation until first progression in the peritoneum or death; assessed with CT/MRI per RECIST v1.1."}
• {"endpoint_text":"- TFST defined as the time from the date of randomisation until the date of first subsequent anticancer therapy or death from any cause, whichever occurs first. Planned post-operative chemotherapy and planned maintenance therapy is considered as a part of the primary treatment and should not be assessed as new subsequent anticancer therapy.","definition_or_measurement_approach":"Time from randomisation to first subsequent anticancer therapy or death; planned post-operative chemotherapy and planned maintenance therapy are not counted as subsequent anticancer therapy."}
• {"endpoint_text":"- TSST defined as the time from the date of randomisation to the date of second subsequent anticancer therapy or death from any cause, whichever occurs first. Planned post-operative chemotherapy and planned maintenance therapy is considered as a part of the primary treatment and should not be assessed as new subsequent anticancer therapy.","definition_or_measurement_approach":"Time from randomisation to second subsequent anticancer therapy or death; planned post-op/maintenance therapy are not counted as subsequent therapy."}
• {"endpoint_text":"- Change in biomarker (CA125).","definition_or_measurement_approach":"Change from baseline in CA125 levels (method not further specified in record)."}
• {"endpoint_text":"- Changes from baseline in patient reported outcome scores using QoL forms European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ- OV28.","definition_or_measurement_approach":"Changes from baseline in patient-reported QoL scores using EORTC QLQ-C30 and QLQ-OV28 instruments."}

Methods

• Possibia Website (K2_Privacy Policy Possibia Website English) — website channel; privacy policy and framework documents provided (documents available associated with country-specific Part II submissions).
• Pre-screener materials (K2_Recruitment material_Pre-screener) — pre-screener documents available in multiple languages (Norwegian, Dutch, French, Italian, Spanish, English) to identify potential participants.
• Patient-facing overview (K2_Recruitment material_Patient facing overview) — overview materials in multiple languages (Norwegian, Dutch, French, Italian, Spanish, English) aimed at potential participants.
• Social media text (K2_Recruitment material_Social media text) — social media recruitment text available in multiple languages (Norwegian, Dutch, French, Spanish, Italian, English).
• Visual media assets and visual explanation pre-screener (K2_Recruitment material_Visual media asset; Visual explanation Pre-Screener) — visual recruitment assets in English and other languages to support online recruitment and patient engagement.
• Country-specific K1_Recruitment arrangements documents — recruitment arrangements documents submitted per Member State (documents associated with Norway, Belgium, Italy, Spain).

Norway

Earliest CTIS Part Ii Submission Date

22-03-2024

Latest Decision Or Authorization Date

27-04-2026

Processing Time Days

766

Number Of Sites

1

Number Of Participants

19

Belgium

Earliest CTIS Part Ii Submission Date

22-03-2024

Latest Decision Or Authorization Date

27-04-2026

Processing Time Days

766

Number Of Sites

1

Number Of Participants

8

Italy

Earliest CTIS Part Ii Submission Date

09-07-2025

Latest Decision Or Authorization Date

29-04-2026

Processing Time Days

294

Number Of Sites

1

Number Of Participants

10

Spain

Earliest CTIS Part Ii Submission Date

22-03-2024

Latest Decision Or Authorization Date

29-04-2026

Processing Time Days

768

Number Of Sites

6

Number Of Participants

38

Primary sponsor

Full Name

Oncoinvent Solutions AS

Organisation Type

Pharmaceutical company

Country Of Registered Address

Norway

Third parties

• {"country":"United States","full_name":"Myriad Genetics Inc.","duties_or_roles":"Myriad MyChoice CDx for HRD status","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"Sweden","full_name":"Viedoc Technologies AB","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
• {"country":"United States","full_name":"Fortrea Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Veeva Systems Inc.","duties_or_roles":"Trial Master File","organisation_type":"Pharmaceutical company"}